Does Canada pay its fair share of the global cost of pharmaceutical innovation?
Brett J Skinner, PhD | CEO, CHPI; Editor, CHPJ | ABSTRACT – The global cost
Research Abstract
The Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications
Yanick Labrie, MA | Health Economist, Yanick Labrie Consultant Inc. | ABSTRACT –
Bulk purchasing for innovative pharmaceuticals – proceed with caution
Neil Palmer | Independent Consultant | ABSTRACT – The promise of substantial additional cost savings
Net direct expenditure on patented medicines by public drug plans in 10 Canadian provinces in 2023
Brett Skinner, PhD | CEO CHPI, Editor CHPJ | ABSTRACT – Canada’s federal, provincial, and
Documenting Long-Acting Reversible Contraceptive (LARC) Coverage Across Canada
Haylie Simmons, BSc; Nichole Austin, PhD; Daniel Dutton, PhD | Dalhousie University | ABSTRACT –
Access to new drugs on public formularies in 10 Canadian provinces 2019 to 2024
Brett Skinner, PhD | CEO CHPI, Editor CHPJ | ABSTRACT –
The impact of pharmaceutical innovation on mortality and hospital utilization in Canada, 2000–2022
Frank R Lichtenberg, PhD | Columbia University, National Bureau of Economic Research | ABSTRACT –